Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era.
- Author:
Eun Sun JANG
1
;
Young Seok KIM
;
Kyung Ah KIM
;
Youn Jae LEE
;
Woo Jin CHUNG
;
In Hee KIM
;
Byung Seok LEE
;
Sook Hyang JEONG
Author Information
- Publication Type:Original Article
- Keywords: Hepacivirus; Therapeutics; Peginterferon alfa; Ribavirin; Sustained virologic response
- MeSH: Antiviral Agents; Cohort Studies; Diagnosis; Genotype; Hepacivirus; Hepatitis C, Chronic*; Hepatitis, Chronic*; Humans; Korea*; Liver; Retrospective Studies; Ribavirin; Tertiary Care Centers
- From:Gut and Liver 2017;11(4):543-550
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: To evaluate the era of direct acting antivirals (DAAs), we must understand the treatment patterns and outcomes of interferon-based therapy for hepatitis C virus (HCV) infection. We aimed to elucidate the treatment rate, factors affecting treatment decisions, and efficacy of interferon-based therapy in a real-world setting. METHODS: This nationwide cohort study included 1,191 newly diagnosed patients with chronic HCV infection at seven tertiary hospitals in South Korea. Subjects were followed retrospectively until March 2015, which was just before the approval of DAA therapy. RESULTS: In total, 48.2% and 49.3% of the patients had HCV genotypes 1 and 2, respectively. Interferon-based therapy was initiated in 541 patients (45.4%). The major reasons for no treatment included ineligibility (18.9%), concern about adverse events (22.3%), cost (21.5%), and an age >75 years (19.5%). Interferon-based therapy was discontinued (18.5%) mainly due to adverse events (n=66). The intent-to-treat analysis found that the sustained virologic response (SVR) rate was 58.3% in genotype 1 patients and 74.7% in non-genotype 1 patients. CONCLUSIONS: Approximately one-third of newly diagnosed HCV patients in South Korea received interferon-based therapy and showed a suboptimal SVR rate. Diagnosis of patients at younger ages and with a less advanced liver status and reducing the DAA therapy cost may fulfill unmet needs.
